💊 Médicaments A-Z 🧬 Cibles 🛠 Outils 📚 Guides
Tous les médicaments Classes de médicaments Aires thérapeutiques Effets Indésirables
Guides Glossaire Chronologie
Comparaisons Parcours des médicaments Familles de médicaments
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Elapegademase

CHEMBL3990026 Phase 4 Approuvé Enzyme
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
248.3 g/mol
LogP
-2.7
Phase
4

This enzyme replacement therapy provides a working version of adenosine deaminase, an enzyme missing in a rare form of severe combined immunodeficiency. Regular injections help restore immune system function in affected patients.

Masse moléculaire

248,2800 g/mol

LogP

-2,70

TPSA

111,00 Ų

Règle des 5 de Lipinski

Conforme

Mécanisme d'action

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

Structure 2D

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCCOC(=O)NCCCC[C@@H](C(=O)O)N

                

                

                
                

                    
InChI

                    
InChI=1S/C10H20N2O5/c1-16-6-7-17-10(15)12-5-3-2-4-8(11)9(13)14/h8H,2-7,11H2,1H3,(H,12,15)(H,13,14)/t8-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C10H20N2O5

                    

                    
                    

                        
HBD / HBA

                        
3 / 6

                    

                    
                    

                        
Liaisons Rotatives

                        
10

                    

                    
                    
                    

                        
Atomes Lourds

                        
17

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Foire aux questions

                

                    
                    

                        
                        

                            
This enzyme replacement therapy provides a working version of adenosine deaminase, an enzyme missing in a rare form of severe combined immunodeficiency. Regular injections help restore immune system function in affected patients.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Provides exogenous replacement of the deficient or absent enzyme, enabling the metabolic processing of accumulated substrates and restoring normal metabolic function.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Elapegademase is an approved drug. It has reached clinical phase 4. It is classified as a Enzyme.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3990026.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 121488177.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Avertissement médical

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.